MC4R and Prader-Willi syndrome: The basis for this medication is that the pro-orexigenic pathways in the hypothalamus, which are apparently normally expressed in the brains of individuals with PWS, can potentially be overcome by activation of the MC4R, thus controlling appetite and improving metabolism.